1-Propanamide, N-ethyl-N-methyl- | 98278-03-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Propanamide, N-ethyl-N-methyl-
• 英文别名: N-ethyl-N-methylpropanamide；N-ethyl-N-methyl-propionamide；N-Aethyl-N-methyl-propionamid；Propionsaeure-(aethyl-methyl-amid)；N-Ethyl-N-methylpropionamide
• CAS: 98278-03-6
• 化学式: C₆H₁₃NO
• 分子量: 115.175
• InChiKey: GHVUKOCVBVUUGS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1-Propanamide, N-ethyl-N-methyl- 在 正丁基锂 、 silver trifluoromethanesulfonate 、 N,N-二异丙基乙胺 、 copper(l) chloride 作用下， 以 四氢呋喃 、 正己烷 、 1,2-二氯乙烷 、 甲苯 为溶剂， 反应 17.0h， 生成 N-ethyl-N,2-dimethyl-3-(2-phenylquinolin-4-yl)propanamide
  参考文献：
  名称：

  Development of N-Methyl-(2-arylquinolin-4-yl)oxypropanamides as Leads to PET Radioligands for Translocator Protein (18 kDa)

  摘要：

  Translocator protein (18 kDa), known as TSPO, is a recognized biomarker of neuroinflammation. Radioligands with PET accurately quantify TSPO in neuroinflammatory conditions. However, the existence of three human TSPO genotypes that show differential affinity to almost all useful TSPO PET radioligands hampers such studies. There is an unmet need for genotype-insensitive, high-affinity, and moderately lipophilic TSPO ligands that may serve as leads for PET radioligand development. To address this need, we varied the known high-affinity TSPO ligand (l)-N,N-diethyl-2-methyl-3-(2-phenylquinolin-4-yl)propanamide in its aryl scaffold, side chain tether, and pendant substituted amido group while retaining an N-methyl group as a site for labeling with carbon-11. From this effort, oxygen-tethered N-methyl-aryloxypropanamides emerged as new high-affinity TSPO ligands with attenuated lipophilicity, including one example with attractive properties for PET radioligand development, namely N-methyl-N-phenyl-2-{[2-(pyridin-2-yl)quinolin-4-yl]oxy}propanamide (22a; rat K-i = 0.10 nM; human TSPO genotypes K-i = 1.4 nM; clogD = 4.18).

  DOI：

  10.1021/jm5007947
• 作为产物：
  描述：

  N-乙基甲基胺 、 alkaline earth salt of/the/ methylsulfuric acid 以57%的产率得到1-Propanamide, N-ethyl-N-methyl-
  参考文献：
  名称：

  羰基取代基对 N-乙基-N-甲基酰胺旋转屏障的影响

  摘要：

  13 α-烷基-和α-卤代N-theyl-N-甲基酰胺围绕C(O)N键旋转的障碍是通过1H NMR光谱在聚结温度下确定的。吉布斯自由能 (ΔG°) 和吉布斯活化能 (ΔG‡) 值与 α-羰基的 Charton 电子和空间参数的关系图可以得出以下结论：异构偏好和围绕 C(O) 旋转的障碍N-乙基-N-甲基酰胺的N键主要取决于α-羰基的空间效应。

  DOI：

  10.1002/mrc.1260310507

文献信息

• [EN] SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] INHIBITEURS DE BÊTA-SÉCRÉTASE DE TYPE SPIROPYRROLIDINE POUR LE TRAITEMENT DE LA MALADIE D'ALZHEIMER
  申请人：MERCK SHARP & DOHME

  公开号：WO2010094242A1

  公开（公告）日：2010-08-26

  The present invention is directed to spiropyrrolidine compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.

  本发明涉及式(I)的螺环吡咯烷化合物，它们是β-分泌酶的抑制剂，并且在治疗涉及β-分泌酶的疾病，如阿尔茨海默病中有用。该发明还涉及包含这些化合物的药物组合物，以及在治疗涉及β-分泌酶的这类疾病中使用这些化合物和组合物。
• ANTIPROLIFERATION COMPOUNDS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20190322658A1

  公开（公告）日：2019-10-24

  The present invention provides compounds of Formula I′, or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof for treating cellular proliferative disorders (e.g., cancer).

  本发明提供了式I′的化合物，或其药学上可接受的盐，以及用于治疗细胞增殖性疾病（例如癌症）的药物组合物和使用方法。
• METHOD FOR MANUFACTURING KETONE
  申请人：Kaneda Kiyotomi

  公开号：US20110288340A1

  公开（公告）日：2011-11-24

  A method for manufacturing a ketone includes oxidizing an internal olefin or a cyclic olefin having one carbon-carbon double bond or more at a position other than terminals of a molecule thereof in an amide-based solvent in the presence of water, a palladium catalyst, and molecular oxygen, thereby bonding an oxo group to at least one of the carbon atoms constituting the carbon-carbon double bond, in which the amide-based solvent is represented by the formula in the formula (1), R 1 represents an alkyl group having 1 to 4 carbon atoms, R 2 and R 3 each independently represent an alkyl group having 1 to 4 carbon atoms or an aryl group, and when R 1 and R 2 are alkyl groups, R 1 and R 2 may be bonded to each other to form a ring structure.

  一种制造酮的方法包括在酰胺基溶剂中氧化内部烯烃或环烯烃，该内部烯烃或环烯烃在其分子的末端以外的位置具有一个或多个碳-碳双键，在水、钯催化剂和分子氧的存在下，将氧基键合到构成碳-碳双键的碳原子之一上。其中，酰胺基溶剂由以下式表示：在公式（1）中，R1代表具有1至4个碳原子的烷基基团，R2和R3分别独立表示具有1至4个碳原子的烷基基团或芳基基团，当R1和R2为烷基基团时，R1和R2可以结合在一起形成环状结构。
• PROCESS FOR PRODUCING ESTER COMPOUND HAVING a,ß-UNSATURATED BOND
  申请人：Kaneda Kiyotomi

  公开号：US20120316360A1

  公开（公告）日：2012-12-13

  A process for producing an α,β-unsaturated bond-containing ester compound, comprising: reacting an internal olefin or a cyclic olefin having one carbon-carbon double bond or more at a position other than terminals of a molecule thereof (the internal olefin and the cyclic olefin may each contain a hetero atom) with a carboxylic acid in an amide-based solvent in the presence of a palladium catalyst, a base, and molecular oxygen, thereby bonding a carboxyl group of the carboxylic acid to at least one of carbon atoms constituting the carbon-carbon double bond and carbon atoms at allylic positions of the internal olefin or the cyclic olefin, to obtain an ester compound having an α,β-unsaturated bond, the amide-based solvent being represented by the following formula (1): (in the formula (1), R 1 represents an alkyl group having 1 to 4 carbon atoms; R 2 and R 3 each independently represent an alkyl group having 1 to 4 carbon atoms or an aryl group; and when R 1 and R 2 are alkyl groups, R 1 and R 2 may be bonded to each other to form a ring structure).

  一种生产α，β-不饱和键含量酯化合物的方法，包括：在存在钯催化剂、碱和分子氧的情况下，将具有一个或多个碳-碳双键的内部烯烃或环烯烃（该内部烯烃和环烯烃可能含有杂原子）与羧酸在酰胺基溶剂中反应，从而将羧基与内部烯烃或环烯烃的烯烃碳原子中至少一个或烯丙位碳原子中的至少一个之一结合，以获得具有α，β-不饱和键的酯化合物，所述酰胺基溶剂由以下式（1）表示：（在式（1）中，R1代表具有1至4个碳原子的烷基基团；R2和R3各自独立地代表具有1至4个碳原子的烷基基团或芳基；当R1和R2为烷基基团时，R1和R2可以结合在一起形成环结构）。
• [EN] COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS<br/>[FR] COMPOSÉS, COMPOSITIONS, PROCÉDÉS POUR LE TRAITEMENT DE MALADIES ET PROCÉDÉS POUR LA PRÉPARATION DE COMPOSÉS
  申请人：UNIV LOUISVILLE RES FOUND INC

  公开号：WO2017019537A1

  公开（公告）日：2017-02-02

  Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

  该发明的一些实施例包括创新化合物（例如，式（I）的化合物）。其他实施例包括包括该创新化合物的组合物（例如，药物组合物）。该发明的另一些实施例包括使用创新化合物的组合物（例如，药物组合物）来治疗，例如使用创新化合物治疗某些疾病。一些实施例包括使用创新化合物的方法（例如，在组合物或药物组合物中）进行给药和治疗（例如，癌症等疾病）。进一步的实施例包括制备创新化合物的方法。此外，本文还讨论了该发明的其他实施例。